[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 29
1. Whittaker DS, Wang HB, Loh DH, Cachope R, Colwell CS: Possible use of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse model of Huntington's disease. Pharmacol Res Perspect; 2017 Oct;5(5)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we sought to determine if the daily administration of the histamine-3 receptor (H3R) antagonist/inverse agonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) would improve nonmotor symptoms in the Q175 line.
  • This class of drugs acts on autoreceptors found at histaminergic synapses and results in increased levels of histamine (HA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
  • [Cites] J Neurosci. 2005 Jan 5;25(1):157-63 [15634777.001]
  • [Cites] J Pharmacol Exp Ther. 2011 Jan;336(1):17-23 [20864502.001]
  • [Cites] J Neurosci. 2001 Mar 1;21(5):1787-94 [11222668.001]
  • [Cites] Behav Brain Res. 2012 Jul 1;232(2):416-20 [22561131.001]
  • [Cites] Mov Disord. 2014 Sep 15;29(11):1359-65 [25154728.001]
  • [Cites] Neurobiol Dis. 2015 May;77:155-64 [25779967.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Apr;313(1):176-90 [15608077.001]
  • [Cites] PLoS One. 2013 Jul 30;8(7):e69993 [23936129.001]
  • [Cites] Nat Protoc. 2006;1(1):7-12 [17406205.001]
  • [Cites] Mov Disord. 2005 Jun;20(6):674-9 [15704211.001]
  • [Cites] Brain Res. 1995 Oct 16;695(2):227-30 [8556334.001]
  • [Cites] Physiol Behav. 1990 Mar;47(3):549-54 [2359768.001]
  • [Cites] Br J Pharmacol. 2004 Nov;143(5):649-61 [15466448.001]
  • [Cites] Neuroendocrinology. 1989 Aug;50(2):187-92 [2550838.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3498-503 [14993615.001]
  • [Cites] Cell Death Differ. 2006 Dec;13(12 ):2068-78 [16729030.001]
  • [Cites] Nature. 2000 Dec 14;408(6814):860-4 [11130725.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(5):695-700 [2906157.001]
  • [Cites] J Vis Exp. 2013 Jul 04;(77):e4367 [23852258.001]
  • [Cites] Brain Pathol. 2011 Jul;21(4):419-27 [21106039.001]
  • [Cites] Neuroscience. 2015 Dec 17;311:519-38 [26546830.001]
  • [Cites] J Neurochem. 2009 Sep;110(5):1469-78 [19549072.001]
  • [Cites] Pharmacol Biochem Behav. 2006 Oct;85(2):332-8 [17049370.001]
  • [Cites] J Neurosci. 2004 Oct 20;24(42):9434-40 [15496679.001]
  • [Cites] J Biol Rhythms. 2012 Feb;27(1):48-58 [22306973.001]
  • [Cites] Eur J Neurosci. 2015 Oct;42(7):2467-77 [26215659.001]
  • [Cites] Minerva Pneumol. 2012 Sep;51(3):93-106 [23687390.001]
  • [Cites] J Neurosci. 2009 Oct 28;29(43):13589-602 [19864571.001]
  • [Cites] Trends Pharmacol Sci. 2004 Dec;25(12):618-25 [15530639.001]
  • [Cites] Physiol Behav. 1992 Feb;51(2):391-4 [1313592.001]
  • [Cites] Brain Res. 1993 Jun 4;613(1):149-51 [8348297.001]
  • [Cites] Mol Pharmacol. 2002 Jan;61(1):239-45 [11752226.001]
  • [Cites] Nature. 1983 Apr 28;302(5911):832-7 [6188956.001]
  • [Cites] Biochem Pharmacol. 2007 Apr 15;73(8):1084-96 [17129577.001]
  • [Cites] J Neurosci. 2002 Sep 1;22(17):7695-711 [12196593.001]
  • [Cites] Nat Rev Neurosci. 2003 Feb;4(2):121-30 [12563283.001]
  • [Cites] Brain Res. 1990 Sep 3;526(2):322-7 [1979518.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(8):1997-2004 [16262638.001]
  • [Cites] Curr Psychiatry Rep. 2014 Dec;16(12):524 [25312027.001]
  • [Cites] CNS Neurol Disord Drug Targets. 2007 Feb;6(1):31-43 [17305552.001]
  • [Cites] Trends Pharmacol Sci. 2000 Aug;21(8):293-8 [10918634.001]
  • [Cites] Clin Chem. 2003 Oct;49(10):1726-32 [14500613.001]
  • [Cites] Bioorg Med Chem Lett. 2013 Dec 15;23(24):6890-6 [24269482.001]
  • [Cites] Physiol Behav. 1991 Mar;49(3):643-6 [1648245.001]
  • [Cites] Nat Rev Neurosci. 2013 Oct;14 (10 ):708-21 [24052178.001]
  • [Cites] Neuron. 2016 Mar 2;89(5):910-26 [26938440.001]
  • [Cites] Neuropsychopharmacology. 2013 May;38(6):1015-31 [23303066.001]
  • [Cites] Neuroscience. 2002;114(1):173-93 [12207964.001]
  • [Cites] PLoS One. 2012;7(12):e50717 [23284644.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13316-20 [8917588.001]
  • [Cites] Neuroscience. 1993 Jan;52(1):169-89 [8381924.001]
  • [Cites] Brain Res. 1990 Jul 23;523(2):325-30 [2169324.001]
  • [Cites] Prog Neurobiol. 2001 Apr;63(6):637-72 [11164999.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Oct;307(1):213-8 [12954820.001]
  • [Cites] J Vis Exp. 2012 Jan 28;(59):e3769 [22315011.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):397-408 [19548255.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jun;321(3):1032-45 [17327487.001]
  • [Cites] Physiol Genomics. 2007 Jan 17;28(2):232-8 [16985007.001]
  • [Cites] J Auton Nerv Syst. 1992 Jun 15;39(2):105-10 [1385510.001]
  • [Cites] Br J Pharmacol. 2009 May;157(1):104-17 [19413575.001]
  • [Cites] J Vis Exp. 2013 Jun 17;(76):null [23851663.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):387-92 [8401587.001]
  • [Cites] Neurobiol Dis. 2008 Apr;30(1):74-83 [18295497.001]
  • [Cites] Brain Res Mol Brain Res. 2004 May 19;124(2):178-87 [15135226.001]
  • [Cites] Pharmacol Ther. 2004 Jul;103(1):1-20 [15251226.001]
  • [Cites] PLoS One. 2012;7(12):e49838 [23284626.001]
  • [Cites] J Pharmacol Exp Ther. 2010 Jan;332(1):164-72 [19815811.001]
  • [Cites] Brain Res. 1984 Mar 12;295(1):13-25 [6713171.001]
  • [Cites] J Biol Rhythms. 1998 Aug;13(4):288-95 [9711504.001]
  • [Cites] Eur J Pharmacol. 2003 Feb 28;463(1-3):3-33 [12600700.001]
  • [Cites] Age (Dordr). 2009 Dec;31(4):293-303 [19557547.001]
  • [Cites] Exp Neurol. 2011 Mar;228(1):80-90 [21184755.001]
  • [Cites] PLoS One. 2015 Dec 10;10(12):e0144694 [26660098.001]
  • [Cites] Sleep. 2012 May 01;35(5):713-5 [22547898.001]
  • [Cites] Neurosci Biobehav Rev. 2005;29(4-5):571-625 [15890404.001]
  • [Cites] Expert Opin Investig Drugs. 2004 Oct;13(10):1237-48 [15461554.001]
  • [Cites] Elife. 2015 Nov 02;4:null [26523393.001]
  • (PMID = 28971617.001).
  • [ISSN] 2052-1707
  • [Journal-full-title] Pharmacology research & perspectives
  • [ISO-abbreviation] Pharmacol Res Perspect
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Circadian rhythms / GSK189254 / Huntington's disease / histamine / histamine-3 receptor / nonmotor symptoms / sleep behavior
  •  go-up   go-down


2. Knadler MP, Lobo E, Chappell J, Bergstrom R: Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet; 2011 May;50(5):281-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An increase in gastric pH produced by histamine H(2)-receptor antagonists or antacids did not impact the absorption of duloxetine.
  • [MeSH-minor] Adult. Aged. Animals. Drug Interactions. Duloxetine Hydrochloride. Female. Humans. Male. Middle Aged. Pharmacogenetics. Risk Assessment. Risk Factors

  • Hazardous Substances Data Bank. DULOXETINE .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropsychopharmacology. 2001 May;24(5):511-21 [11282251.001]
  • [Cites] J Cardiovasc Pharmacol. 2007 Jun;49(6):384-93 [17577103.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Jul 5;14(13):3481-6 [15177457.001]
  • [Cites] Am J Geriatr Psychiatry. 2005 Mar;13(3):227-35 [15728754.001]
  • [Cites] Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70 [15589385.001]
  • [Cites] Curr Pharm Des. 2005;11(12):1475-93 [15892657.001]
  • [Cites] Pharmacopsychiatry. 2008 Jul;41(4):151-5 [18651344.001]
  • [Cites] Eur J Clin Pharmacol. 1998 Jan;53(5):361-7 [9516038.001]
  • [Cites] Br J Clin Pharmacol. 2004 May;57(5):652-6 [15089819.001]
  • [Cites] Neuropsychopharmacology. 1993 Jan;8(1):23-33 [8424846.001]
  • [Cites] Clin Pharmacol Ther. 2003 Mar;73(3):170-7 [12621382.001]
  • [Cites] Psychopharmacol Bull. 2002 Autumn;36(4):106-32 [12858150.001]
  • [Cites] Clin Pharmacol Ther. 1992 Dec;52(6):643-58 [1458773.001]
  • [Cites] Pharmacopsychiatry. 2009 Sep;42(5):189-93 [19724981.001]
  • [Cites] Psychosomatics. 2005 May-Jun;46(3):262-73 [15883149.001]
  • [Cites] Br J Clin Pharmacol. 2007 Mar;63(3):310-4 [17380590.001]
  • [Cites] Clin Pharmacokinet. 2010 May;49(5):311-21 [20384393.001]
  • [Cites] Pain Med. 2005 Sep-Oct;6(5):346-56 [16266355.001]
  • [Cites] Int Clin Psychopharmacol. 1997 May;12(3):137-40 [9248869.001]
  • [Cites] Clin Ther. 2007 Dec;29(12):2706-9 [18201587.001]
  • [Cites] Br J Clin Pharmacol. 1994 Feb;37(2):125-8 [8186058.001]
  • [Cites] Int J Clin Pharmacol Ther. 2005 Feb;43(2):78-84 [15726876.001]
  • [Cites] BMJ. 1999 Oct 23;319(7217):1106-9 [10531103.001]
  • [Cites] J Clin Psychopharmacol. 2006 Dec;26(6):681-3 [17110838.001]
  • [Cites] Drug Metab Dispos. 2008 Dec;36(12 ):2484-91 [18809731.001]
  • [Cites] J Psychiatr Res. 2002 Nov-Dec;36(6):383-90 [12393307.001]
  • [Cites] Clin Pharmacokinet. 2009;48(3):189-97 [19385712.001]
  • [Cites] Neuropsychopharmacology. 2001 Dec;25(6):871-80 [11750180.001]
  • [Cites] Pain. 2005 Jul;116(1-2):109-18 [15927394.001]
  • [Cites] BJU Int. 2004 Feb;93(3):311-8 [14764128.001]
  • [Cites] Psychopharmacology (Berl). 2006 Apr;185(3):395-9 [16506079.001]
  • [Cites] J Clin Pharmacol. 2000 Feb;40(2):161-7 [10664922.001]
  • [Cites] Drug Saf. 2007;30(5):437-55 [17472422.001]
  • [Cites] J Clin Pharmacol. 2003 May;43(5):443-69 [12751267.001]
  • [Cites] Depress Anxiety. 2008;25(3):182-9 [17311303.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):100-5 [17316589.001]
  • [Cites] J Clin Psychiatry. 2009 Feb;70(2):208-13 [19210951.001]
  • [Cites] Am J Geriatr Pharmacother. 2005 Mar;3(1):25-38 [16089245.001]
  • [Cites] Clin Pharmacokinet. 2007;46(9):767-75 [17713974.001]
  • [Cites] Br J Clin Pharmacol. 2004 Jan;57(1):54-61 [14678340.001]
  • [Cites] J Clin Psychiatry. 2006 Nov;67(11):1821-2 [17196070.001]
  • [Cites] J Psychopharmacol. 2009 Nov;23(8):875-82 [18583440.001]
  • [Cites] J Clin Psychopharmacol. 2004 Aug;24(4):389-99 [15232330.001]
  • [Cites] Clin Pharmacol Ther. 2002 Mar;71(3):115-21 [11907485.001]
  • [Cites] Int Clin Psychopharmacol. 2007 May;22(3):167-74 [17414743.001]
  • [Cites] J Cardiovasc Pharmacol. 2007 Mar;49(3):146-53 [17414226.001]
  • [Cites] Arthritis Rheum. 2004 Sep;50(9):2974-84 [15457467.001]
  • [Cites] J Clin Psychopharmacol. 2007 Feb;27(1):28-34 [17224709.001]
  • [Cites] Clin Pharmacokinet. 2008;47(2):103-9 [18193916.001]
  • [Cites] Curr Med Res Opin. 2007 Jan;23(1):175-84 [17257478.001]
  • [Cites] Expert Opin Drug Saf. 2005 Nov;4(6):987-93 [16255658.001]
  • [Cites] Neuropsychopharmacology. 2003 Sep;28(9):1685-93 [12784100.001]
  • [Cites] JAMA. 2006 Apr 5;295(13):1517-8 [16595756.001]
  • [Cites] J Clin Psychiatry. 2002 Apr;63(4):308-15 [12000204.001]
  • [Cites] Curr Med Res Opin. 2007 Jun;23(6):1245-52 [17559726.001]
  • [Cites] J Clin Pharmacol. 2009 Dec;49(12):1456-66 [19793910.001]
  • [Cites] Clin Pharmacokinet. 2008;47(3):191-202 [18307373.001]
  • [Cites] Drug Metab Dispos. 2003 Sep;31(9):1142-50 [12920170.001]
  • [Cites] Depress Anxiety. 2008;25(7):E1-11 [17587217.001]
  • (PMID = 21366359.001).
  • [ISSN] 1179-1926
  • [Journal-full-title] Clinical pharmacokinetics
  • [ISO-abbreviation] Clin Pharmacokinet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adrenergic Uptake Inhibitors; 0 / Serotonin Uptake Inhibitors; 0 / Thiophenes; 9044SC542W / Duloxetine Hydrochloride
  •  go-up   go-down


3. Zaki Rizkalla CM, latif Aziz R, Soliman II: In vitro and in vivo evaluation of hydroxyzine hydrochloride microsponges for topical delivery. AAPS PharmSciTech; 2011 Sep;12(3):989-1001
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro and in vivo evaluation of hydroxyzine hydrochloride microsponges for topical delivery.
  • Therefore, the aim of the present study was to produce an effective drug-loaded dosage form that is able to control the release of hydroxyzine hydrochloride into the skin.
  • The pharmacodynamic effect of the chosen preparation was tested on the shaved back of histamine-sensitized rabbits.

  • Hazardous Substances Data Bank. STEARIC ACID .
  • Hazardous Substances Data Bank. HYDROXYZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Microencapsul. 1991 Jul-Sep;8(3):401-6 [1941447.001]
  • [Cites] J Microencapsul. 1986 Oct-Dec;3(4):305-16 [3508191.001]
  • [Cites] J Microencapsul. 1995 Jan-Feb;12(1):71-81 [7730959.001]
  • [Cites] J Microencapsul. 1997 Nov-Dec;14(6):725-33 [9394253.001]
  • [Cites] J Control Release. 1999 Mar 8;58(1):9-20 [10021485.001]
  • [Cites] Farmaco. 2005 Mar;60(3):261-7 [15784247.001]
  • [Cites] Int J Pharm. 2005 Apr 27;294(1-2):33-51 [15814229.001]
  • [Cites] J Microencapsul. 2005 Feb;22(1):81-90 [16019893.001]
  • [Cites] J Pharm Biomed Anal. 2006 Mar 3;40(4):910-4 [16242283.001]
  • [Cites] AAPS PharmSciTech. 2006;7(1):E16 [16584146.001]
  • [Cites] Eur J Pharm Biopharm. 2006 Jun;63(2):140-5 [16531026.001]
  • [Cites] Int J Pharm. 2007 Jun 29;338(1-2):231-7 [17368983.001]
  • [Cites] AAPS PharmSciTech. 2008;9(1):154-62 [18446476.001]
  • [Cites] J Microencapsul. 2010;27(4):314-24 [19839785.001]
  • [Cites] J Allergy Clin Immunol. 2001 Mar;107(3):526-30 [11240955.001]
  • [Cites] Int J Pharm. 2002 Aug 21;242(1-2):107-13 [12176232.001]
  • [Cites] Int J Pharm. 2003 Feb 18;252(1-2):99-109 [12550785.001]
  • [Cites] Int J Pharm. 2004 Jan 9;269(1):131-40 [14698584.001]
  • [Cites] AAPS PharmSci. 2003 Nov 5;5(4):E28 [15198516.001]
  • [Cites] Int J Pharm. 2004 Aug 6;280(1-2):57-65 [15265547.001]
  • [Cites] Science. 1972 Feb 18;175(4023):720-31 [4333397.001]
  • [Cites] Yakugaku Zasshi. 1985 Nov;105(11):1087-95 [3835255.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1986 Jun;34(6):2618-23 [3769077.001]
  • [Cites] J Microencapsul. 1986 Oct-Dec;3(4):293-304 [3508190.001]
  • [Cites] J Microencapsul. 1994 Mar-Apr;11(2):153-9 [8006762.001]
  • (PMID = 21800216.001).
  • [ISSN] 1530-9932
  • [Journal-full-title] AAPS PharmSciTech
  • [ISO-abbreviation] AAPS PharmSciTech
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylic Resins; 0 / Antipruritics; 0 / Delayed-Action Preparations; 0 / Emulsions; 0 / Solvents; 0 / Stearic Acids; 30S50YM8OG / Hydroxyzine; 33434-24-1 / Eudragit RS; 4ELV7Z65AP / stearic acid
  • [Other-IDs] NLM/ PMC3167254
  •  go-up   go-down


Advertisement
4. Yang H, Yoon M, Um MY, Lee J, Jung J, Lee C, Kim YT, Kwon S, Kim B, Cho S: Sleep-Promoting Effects and Possible Mechanisms of Action Associated with a Standardized Rice Bran Supplement. Nutrients; 2017 May 18;9(5)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, both RBS (1000 mg/kg) and doxepin hydrochloride (histamine H₁ receptor antagonist, 30 mg/kg) counteracted a caffeine-induced sleep disturbance in mice.
  • Lastly, we unveiled a possible mechanism for RBS action as the hypnotic effect of RBS was blocked by a histamine H₁ receptor agonist.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CNS Neurosci Ther. 2012 Aug;18(8):623-30 [22632633.001]
  • [Cites] J Ethnopharmacol. 2009 Mar 18;122(2):245-50 [19330921.001]
  • [Cites] Expert Opin Pharmacother. 2008 Feb;9(3):351-62 [18220487.001]
  • [Cites] Neuropsychopharmacology. 2004 Oct;29(10):1933-9 [15257305.001]
  • [Cites] Neurosci Biobehav Rev. 2009 Jun;33(6):874-99 [19428498.001]
  • [Cites] Bioresour Technol. 2008 Jul;99(11):5011-9 [17949974.001]
  • [Cites] J Neurosci. 1996 Feb 15;16(4):1523-37 [8778302.001]
  • [Cites] Nat Rev Neurosci. 2009 Mar;10(3):199-210 [19209176.001]
  • [Cites] Mol Nutr Food Res. 2012 Feb;56(2):304-8 [22038919.001]
  • [Cites] Nat Sci Sleep. 2017 Mar 17;9:97-108 [28360539.001]
  • [Cites] Sleep Med. 2004 Jun;5 Suppl 1:S23-30 [15301994.001]
  • [Cites] Clin Ther. 2006 Oct;28(10):1540-55 [17157111.001]
  • [Cites] CNS Neurol Disord Drug Targets. 2007 Feb;6(1):31-43 [17305552.001]
  • [Cites] Nat Neurosci. 2005 Jul;8(7):858-9 [15965471.001]
  • [Cites] Crit Rev Food Sci Nutr. 2014;54(6):807-16 [24345050.001]
  • [Cites] Nat Rev Neurosci. 2008 Dec;9(12):910-9 [18985047.001]
  • [Cites] Sleep Med Rev. 2011 Apr;15(2):99-106 [20965131.001]
  • [Cites] J Agric Food Chem. 2013 Nov 13;61(45):10626-41 [24175575.001]
  • [Cites] Nutrition. 2016 Nov-Dec;32(11-12):1193-9 [27377580.001]
  • [Cites] Neuropharmacology. 1988 Feb;27(2):111-22 [2965315.001]
  • [Cites] Pharmacol Biochem Behav. 2000 Jan 1;65(1):155-62 [10638649.001]
  • [Cites] Am J Manag Care. 2006 May;12(8 Suppl):S214-20 [16686591.001]
  • [Cites] J Ethnopharmacol. 2010 Jul 6;130(1):163-6 [20347951.001]
  • [Cites] Neurosci Lett. 2012 Sep 13;525(2):95-9 [22897877.001]
  • [Cites] Planta Med. 2007 Sep;73(11):1148-55 [17823876.001]
  • [Cites] Brain Res Brain Res Rev. 1992 May-Aug;17(2):139-70 [1356551.001]
  • [Cites] Eur J Pharmacol. 2014 Dec 5;744:157-63 [25446916.001]
  • [Cites] J Clin Pharm Ther. 2009 Oct;34(5):555-60 [19753680.001]
  • [Cites] Sleep Med Rev. 2000 Jun;4(3):229-251 [12531167.001]
  • (PMID = 28524102.001).
  • [ISSN] 2072-6643
  • [Journal-full-title] Nutrients
  • [ISO-abbreviation] Nutrients
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; caffeine-induced arousal / histaminergic / hypnotic / rice bran / sleep-promoting
  •  go-up   go-down


5. Matsubara R, Kumagai K, Shigematsu H, Kitaura K, Nakasone Y, Suzuki S, Hamada Y, Suzuki R: Fexofenadine Suppresses Delayed-Type Hypersensitivity in the Murine Model of Palladium Allergy. Int J Mol Sci; 2017 Jun 25;18(7)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated inhibition of the immune response in palladium allergic mice by administration of prednisolone as a glucocorticoid and fexofenadine hydrochloride as an antihistamine.
  • Compared with glucocorticoids, fexofenadine hydrochloride significantly suppressed the number of T cells by interfering with the development of antigen-presenting cells from the sensitization phase.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Immunopharmacol. 2016 Jun;35:70-76 [27035718.001]
  • [Cites] Clin Dermatol. 2011 May-Jun;29(3):287-94 [21496736.001]
  • [Cites] Curr Opin Immunol. 2016 Oct;42:25-30 [27228132.001]
  • [Cites] Am J Contact Dermat. 2003 Jun;14(2):78-81 [14749025.001]
  • [Cites] J Am Acad Dermatol. 2000 Jun;42(6):1021-5 [10827407.001]
  • [Cites] Front Biosci (Landmark Ed). 2012 Jan 01;17:40-53 [22201731.001]
  • [Cites] PLoS One. 2014 Jan 20;9(1):e85983 [24465826.001]
  • [Cites] Cell Immunol. 2003 Jul;224(1):47-54 [14572800.001]
  • [Cites] Ann Allergy Asthma Immunol. 1997 Nov;79(5):443-8 [9396979.001]
  • [Cites] Immunology. 1995 Aug;85(4):621-9 [7558158.001]
  • [Cites] J Trace Elem Med Biol. 2015;31:230-6 [25636536.001]
  • [Cites] Clin Exp Immunol. 2009 Jul;157(1):27-34 [19659767.001]
  • [Cites] Eur J Immunol. 1995 Dec;25(12):3308-15 [8566016.001]
  • [Cites] Exp Anim. 2011;60(5):481-7 [22041285.001]
  • [Cites] J Invest Dermatol. 2014 Nov;134(11):2709-18 [24756110.001]
  • [Cites] Expert Opin Drug Saf. 2015 Feb;14(2):199-206 [25466429.001]
  • [Cites] J Invest Dermatol. 2013 Feb;133(2):303-15 [22931926.001]
  • [Cites] Contact Dermatitis. 2009 Jun;60(6):339-43 [19489970.001]
  • [Cites] Nat Immunol. 2010 Sep;11(9):814-9 [20711192.001]
  • [Cites] PLoS One. 2011;6(9):e25538 [21980488.001]
  • [Cites] Int Immunopharmacol. 2003 Jul;3(7):909-20 [12810348.001]
  • [Cites] J Immunol. 1985 Dec;135(6):3929-32 [2415590.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):4102-12 [16547246.001]
  • [Cites] Allergy. 2012 Dec;67(12):1605-8 [23067003.001]
  • [Cites] Allergy. 2000 Feb;55(2):108-15 [10726725.001]
  • [Cites] J Dermatol Sci. 2002 Dec;30(3):180-4 [12443840.001]
  • [Cites] Pharmacol Ther. 2007 Jan;113(1):1-15 [16890992.001]
  • [Cites] J Dermatol Sci. 2008 Jan;49(1):88-91 [17950577.001]
  • [Cites] Int J Mol Sci. 2016 Feb 02;17 (2):null [26848658.001]
  • [Cites] PLoS One. 2014 Feb 12;9(2):e86810 [24533050.001]
  • [Cites] Dermatitis. 2014 Sep-Oct;25(5):273-4 [25207689.001]
  • [Cites] PLoS One. 2013 Oct 03;8(10):e76385 [24098486.001]
  • [Cites] Allergy. 2014 Dec;69(12):1571-81 [25283085.001]
  • [Cites] Br J Dermatol. 2004 Dec;151(6):1133-42 [15606507.001]
  • [Cites] J Allergy Clin Immunol. 2002 Jul;110(1):85-95 [12110826.001]
  • [Cites] Clin Exp Allergy. 2009 Dec;39(12):1786-800 [20085595.001]
  • [Cites] Clin Exp Allergy. 2005 Jan;35(1):97-103 [15649273.001]
  • [Cites] Contact Dermatitis. 2011 Apr;64(4):185-95 [21392026.001]
  • [Cites] Clin Rev Allergy Immunol. 2007 Oct;33(1-2):134-43 [18094952.001]
  • [Cites] Jpn J Infect Dis. 2008 Jan;61(1):40-8 [18219133.001]
  • [Cites] Cell Immunol. 2013 Jul-Aug;284(1-2):163-71 [23978680.001]
  • [Cites] Contact Dermatitis. 2015 Jan;72(1):11-9 [25348727.001]
  • [Cites] Eur J Dermatol. 2012 Sep-Oct;22(5):697-8 [22759481.001]
  • [Cites] Int J Mol Sci. 2016 Jan 12;17 (1):null [26771600.001]
  • [Cites] Allergy. 2012 Dec;67(12):1580-5 [23033862.001]
  • [Cites] J Immunol. 2011 Oct 15;187(8):3919-30 [21908734.001]
  • [Cites] Int Arch Allergy Immunol. 2010;153(3):303-14 [20484930.001]
  • (PMID = 28672829.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; anti histamine / corticosteroid / fexofenadine hydrochloride / metal allergy / palladium
  •  go-up   go-down


6. Zarrindast MR, Taheri S, Rezayof A: The effects of histaminergic agents in the nucleus accumbens of rats in the elevated plus-maze test of anxiety. Iran J Psychiatry; 2010;5(1):11-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are reports indicating that central histamine systems are involved in many physiological behavioral processes, including anxiety.
  • METHODS: Rats were anesthetized with intra-peritoneal injection of ketamine hydrochloride, plus xylazine and then were placed in a stereotaxic apparatus.
  • RESULTS: Intra-NAc administration of histamine (0.01, 0.1 and 1 µg/rat) increased the percentage of open arm time (%OAT) and open arm entries (%OAE), but not locomotor activity, indicating an anxiolytic response.
  • However, both histamine and histamine receptor antagonists showed an anxiolytic-like effect; the antagonists (1 µg/rat) also decreased the histamine response.
  • CONCLUSION: The results may indicate a modulatory effect for the H(1) and H(2) histamine receptors of nucleus accumbens in the anxiety behavior of rats.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1976 Mar 11;260(5547):163-5 [3741.001]
  • [Cites] Physiol Rev. 1991 Jan;71(1):1-51 [1846044.001]
  • [Cites] J Exp Biol. 1986 Sep;124:203-24 [2428901.001]
  • [Cites] J Neurosci Methods. 1985 Aug;14(3):149-67 [2864480.001]
  • [Cites] Physiol Behav. 1986;37(1):39-45 [3016772.001]
  • [Cites] J Neurochem. 1994 Feb;62(2):519-27 [8294914.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1998 May;357(5):508-13 [9650802.001]
  • [Cites] Neuropharmacology. 1998 Aug;37(8):1019-32 [9833631.001]
  • [Cites] Prog Neurobiol. 2001 Apr;63(6):637-72 [11164999.001]
  • [Cites] Behav Brain Res. 2001 Oct 15;124(2):195-202 [11640973.001]
  • [Cites] Pharmacol Biochem Behav. 2002 May;72(1-2):437-41 [11900817.001]
  • [Cites] Neurosci Biobehav Rev. 2004 May;28(3):273-83 [15225971.001]
  • [Cites] Physiol Behav. 2006 May 30;87(5):891-6 [16600315.001]
  • [Cites] Pharmacol Biochem Behav. 2006 Nov;85(3):500-6 [17109942.001]
  • [Cites] J Comp Neurol. 1988 Jul 15;273(3):283-300 [3062046.001]
  • [Cites] Brain Res. 1986 Mar 19;368(2):389-93 [3516308.001]
  • [Cites] Brain Res. 1986 Jan 1;362(1):195-8 [3942865.001]
  • [Cites] J Neurobiol. 1982 Jan;13(1):23-37 [6120210.001]
  • [Cites] Brain Res. 1984 Mar 12;295(1):13-25 [6713171.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1994 Dec;350(6):599-604 [7535897.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jun 15;211(2):570-7 [7794271.001]
  • [Cites] Fundam Clin Pharmacol. 1994;8(2):128-37 [8020871.001]
  • [Cites] Pharmacol Biochem Behav. 1995 Oct;52(2):297-303 [8577794.001]
  • [Cites] Life Sci. 1998;62(17-18):1607-10 [9585144.001]
  • [Cites] Braz J Med Biol Res. 1997 Dec;30(12):1451-61 [9686166.001]
  • [Cites] Neuroscience. 1998 Nov;87(2):479-87 [9740406.001]
  • [Cites] Behav Brain Res. 1999 Jul;102(1-2):171-80 [10403025.001]
  • [Cites] Neuroscience. 1999;94(1):93-103 [10613500.001]
  • [Cites] Ann N Y Acad Sci. 2000;909:270-2 [10911939.001]
  • [Cites] Brain Res Bull. 2001 May 1;55(1):117-21 [11427346.001]
  • [Cites] Pharmacol Biochem Behav. 2002 Jan-Feb;71(1-2):313-8 [11812538.001]
  • [Cites] Pharmacol Biochem Behav. 2003 Apr;75(1):25-33 [12759110.001]
  • [Cites] Eur J Neurosci. 2004 Aug;20(4):1051-8 [15305873.001]
  • [Cites] Behav Brain Res. 2006 Jan 6;166(1):184-7 [16168500.001]
  • [Cites] Behav Pharmacol. 2005 Dec;16(8):643-9 [16286816.001]
  • (PMID = 22952484.001).
  • [ISSN] 1735-4587
  • [Journal-full-title] Iranian journal of psychiatry
  • [ISO-abbreviation] Iran J Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3430404
  • [Keywords] NOTNLM ; Anxiety / Histamine / Maze learning / Pyrilamine / Ranitidine / Rats
  •  go-up   go-down


7. Pytka K, Głuch-Lutwin M, Knutelska J, Jakubczyk M, Waszkielewicz A, Kotańska M: HBK-14 and HBK-15 Do Not Influence Blood Pressure, Lipid Profile, Glucose Level, or Liver Enzymes Activity after Chronic Treatment in Rats. PLoS One; 2016;11(10):e0165495
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1-[(2,6-dimethylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride (HBK-14) and 1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride (HBK-15).
  • [MeSH-minor] Animals. Guinea Pigs. Hep G2 Cells. Histamine / pharmacology. Humans. Ileum / drug effects. Ileum / physiology. Male. Muscle Contraction / drug effects. Rats. Time Factors

  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • Hazardous Substances Data Bank. PIPERAZINE .
  • Hazardous Substances Data Bank. PIPERAZINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. HISTAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS One. 2015 Nov 10;10(11):e0142499 [26554929.001]
  • [Cites] Psychopharmacol Bull. 1994;30(2):145-50 [7831447.001]
  • [Cites] Br J Pharmacol Chemother. 1959 Mar;14(1):48-58 [13651579.001]
  • [Cites] Med Hypotheses. 2010 May;74(5):955-6 [20031337.001]
  • [Cites] Br J Psychiatry. 2005 Oct;187:352-9 [16199795.001]
  • [Cites] Pharmacol Biochem Behav. 2015 Jun;133:99-110 [25847619.001]
  • [Cites] Diabetes. 2008 Sep;57(9):2453-60 [18567822.001]
  • [Cites] Anal Biochem. 1968 Oct 24;25(1):192-205 [4973948.001]
  • [Cites] Indian J Psychol Med. 2014 Apr;36(2):129-33 [24860211.001]
  • [Cites] Int J Behav Med. 2014 Aug;21(4):590-6 [24136399.001]
  • [Cites] Am J Psychiatry. 2014 Apr;171(4):404-15 [24362450.001]
  • [Cites] J Clin Psychiatry. 2003 Dec;64(12):1455-9 [14728107.001]
  • [Cites] Indian J Med Res. 1992 Feb;96:65-71 [1597334.001]
  • [Cites] J Pediatr. 2016 Feb;169:313-5.e1 [26597434.001]
  • [Cites] J Pharm Pharmacol. 1999 Jun;51(6):741-3 [10454053.001]
  • [Cites] Psychiatry Res. 1990 May;32(2):207-9 [2367607.001]
  • [Cites] PLoS One. 2016 Jan 25;11(1):e0147238 [26808533.001]
  • [Cites] Diabetologia. 2006 May;49(5):837-45 [16520921.001]
  • [Cites] Diabetes Care. 2008 Dec;31(12):2383-90 [19033418.001]
  • [Cites] Eur J Pharmacol. 2016 Apr 5;776:146-55 [26896778.001]
  • [Cites] J Affect Disord. 2001 Apr;64(1):43-51 [11292519.001]
  • [Cites] Front Pharmacol. 2016 Aug 03;7:229 [27536240.001]
  • [Cites] BMJ Case Rep. 2013 Sep 26;2013:null [24072839.001]
  • [Cites] Dig Dis Sci. 2009 Jul;54(7):1589-91 [18958618.001]
  • [Cites] Curr Pharm Des. 2004;10(20):2463-75 [15320756.001]
  • [Cites] J Clin Pharmacol. 2016 Jun;56(6):769-78 [26470856.001]
  • [Cites] Life Sci. 1979 Oct 1;25(14):1237-42 [316092.001]
  • [Cites] Obes Res. 2002 Jul;10(7):633-41 [12105285.001]
  • [Cites] Expert Opin Drug Saf. 2006 Jul;5(4):523-37 [16774491.001]
  • [Cites] Chem Biol Drug Des. 2015 Mar;85(3):326-35 [25048712.001]
  • [Cites] Anal Biochem. 1996 Jul 15;239(1):70-6 [8660627.001]
  • [Cites] J Clin Psychopharmacol. 2004 Oct;24(5):527-31 [15349009.001]
  • [Cites] Curr Pharm Des. 2012;18(36):5900-19 [22681169.001]
  • [Cites] J Food Sci Technol. 2011 Aug;48(4):412-22 [23572765.001]
  • [Cites] Cell Biol Toxicol. 2012 Apr;28(2):69-87 [22258563.001]
  • [Cites] J Clin Epidemiol. 1997 Mar;50(3):313-20 [9120531.001]
  • (PMID = 27788267.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / HBK-14; 0 / HBK-15; 0 / Lipids; 0 / Phenyl Ethers; 0 / Piperazines; 1RTM4PAL0V / piperazine; 820484N8I3 / Histamine
  •  go-up   go-down


8. Feng S, Zhu L, Huang Z, Wang H, Li H, Zhou H, Lu L, Wang Y, Liu Z, Liu L: Controlled release of optimized electroporation enhances the transdermal efficiency of sinomenine hydrochloride for treating arthritis in vitro and in clinic. Drug Des Devel Ther; 2017;11:1737-1752
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controlled release of optimized electroporation enhances the transdermal efficiency of sinomenine hydrochloride for treating arthritis in vitro and in clinic.
  • Sinomenine hydrochloride (SH) is an ideal drug for the treatment of rheumatoid arthritis and osteoarthritis.
  • However, high plasma concentration of systemically administered SH can release histamine, which can cause rash and gastrointestinal side effects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Pharm Bull. 2014;37(8):1373-82 [24931312.001]
  • [Cites] Mod Rheumatol. 2016 Sep 23;:1-11 [27659504.001]
  • [Cites] Drug Des Devel Ther. 2016 May 19;10 :1695-701 [27274203.001]
  • [Cites] AJR Am J Roentgenol. 2006 Sep;187(3):794-9 [16928947.001]
  • [Cites] Pharmaceutics. 2016 Mar 17;8(1):null [26999191.001]
  • [Cites] Semin Arthritis Rheum. 2000 Apr;29(5):305-20 [10805355.001]
  • [Cites] Pharmaceutics. 2015 Oct 22;7(4):438-70 [26506371.001]
  • [Cites] Life Sci. 2006 Aug 15;79(12):1203-6 [16643957.001]
  • [Cites] Int J Mol Sci. 2015 Jan 23;16(2):2559-73 [25625512.001]
  • [Cites] J Oleo Sci. 2013;62(9):657-64 [24005010.001]
  • [Cites] Pak J Pharm Sci. 2008 Oct;21(4):407-10 [18930863.001]
  • [Cites] Pharmaceutics. 2016 Nov 15;8(4):null [27854292.001]
  • [Cites] J Control Release. 2013 Dec 28;172(3):862-71 [24113487.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Nov 14;376(2):352-7 [18782565.001]
  • [Cites] IEEE Trans Biomed Eng. 2008 Jul;55(7):1927-30 [18595814.001]
  • [Cites] Nan Fang Yi Ke Da Xue Xue Bao. 2006 Dec;26(12):1709-13 [17259103.001]
  • [Cites] Int J Nanomedicine. 2014 Jul 25;9:3539-50 [25114524.001]
  • [Cites] Pharm Biol. 2012 Aug;50(8):1053-61 [22775422.001]
  • [Cites] Planta Med. 2008 Oct;74(12):1423-9 [18683125.001]
  • [Cites] Yakugaku Zasshi. 2010 Aug;130(8):1053-60 [20686209.001]
  • [Cites] Am J Ther. 2016 Nov/Dec;23 (6):e1560-e1567 [25782568.001]
  • [Cites] Annu Rev Biomed Eng. 2014 Jul 11;16:295-320 [24905876.001]
  • [Cites] Molecules. 2014 Aug 12;19(8):12065-77 [25120057.001]
  • [Cites] Life Sci. 2005 Nov 4;77(25):3197-209 [16019035.001]
  • [Cites] J Drug Target. 2010 Nov;18(9):657-64 [20038213.001]
  • [Cites] Int Immunopharmacol. 2016 Nov;40:492-500 [27769021.001]
  • [Cites] Sports Med Arthrosc Rehabil Ther Technol. 2012 Jan 10;4:3 [22230247.001]
  • [Cites] Pharm Dev Technol. 2017 Jun;22(4):597-605 [27492948.001]
  • [Cites] Rheumatol Int. 2016 Nov;36(11):1557-1561 [27549792.001]
  • [Cites] Int J Nanomedicine. 2015 Jul 10;10:4581-92 [26229462.001]
  • [Cites] Biomed Chromatogr. 2015 Jun;29(6):883-9 [25376167.001]
  • [Cites] Int J Pharm. 2013 Sep 15;454(1):302-9 [23830940.001]
  • [Cites] Genet Mol Res. 2015 Dec 29;14 (4):18928-35 [26782542.001]
  • [Cites] Autoimmun Rev. 2012 Sep;11(11):801-3 [22349616.001]
  • [Cites] Gastroenterol Res Pract. 2013;2013:268382 [24382953.001]
  • [Cites] J Control Release. 2012 Apr 10;159(1):52-9 [22265694.001]
  • [Cites] J Biomech Eng. 2015 Dec;137(12):124501 [26458195.001]
  • [Cites] Molecules. 2015 Apr 10;20(4):6454-65 [25867830.001]
  • [Cites] J Pharm Sci. 2014 Jun;103(6):1638-42 [24648369.001]
  • [Cites] Biomed Opt Express. 2015 Dec 08;7(1):67-78 [26819818.001]
  • [Cites] Eur J Pharmacol. 2013 Dec 5;721(1-3):5-11 [24120369.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10504-8 [8248137.001]
  • (PMID = 28670109.001).
  • [ISSN] 1177-8881
  • [Journal-full-title] Drug design, development and therapy
  • [ISO-abbreviation] Drug Des Devel Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Keywords] NOTNLM ; arthritis / electroporation / sinomenine hydrochloride / transdermal drug delivery
  •  go-up   go-down


9. Makino T, Takegami Y, Rehman MU, Yoshihisa Y, Ishida W, Toyomoto T, Shimizu T: Maintenance of remission with low-dose olopatadine hydrochloride for itch in well-controlled chronic urticaria. Clin Cosmet Investig Dermatol; 2012;5:141-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maintenance of remission with low-dose olopatadine hydrochloride for itch in well-controlled chronic urticaria.
  • Olopatadine hydrochloride is one of the second-generation nonsedating antihistamines.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 1990 Sep;150(9):1881-4 [2102668.001]
  • [Cites] J Drugs Dermatol. 2010 May;9(5):503-12 [20480793.001]
  • [Cites] Br J Dermatol. 1997 Feb;136(2):197-201 [9068731.001]
  • [Cites] Br J Dermatol. 2000 Aug;143(2):365-72 [10951147.001]
  • [Cites] J Am Acad Dermatol. 2001 Sep;45(3):387-91 [11511835.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):110-3 [11841375.001]
  • [Cites] Arch Dermatol Res. 2008 Jul;300(6):291-5 [18305947.001]
  • [Cites] Arch Dermatol Res. 2012 May;304(4):263-72 [22130869.001]
  • [Cites] Jpn J Pharmacol. 2002 Apr;88(4):379-97 [12046981.001]
  • [Cites] Clin Allergy Immunol. 2002;17:337-88 [12113223.001]
  • [Cites] J Dermatol. 2002 Nov;29(11):709-12 [12484432.001]
  • [Cites] Curr Opin Allergy Clin Immunol. 2003 Oct;3(5):363-8 [14501436.001]
  • [Cites] Hum Psychopharmacol. 2003 Dec;18(8):611-8 [14696020.001]
  • [Cites] Clin Exp Dermatol. 2004 Sep;29(5):526-32 [15347340.001]
  • [Cites] Drugs. 2004;64(22):2515-36 [15516152.001]
  • [Cites] Arzneimittelforschung. 2004;54(12):809-29 [15646365.001]
  • [Cites] Cutis. 2005 Aug;76(2):118-26 [16209158.001]
  • [Cites] Br J Dermatol. 2006 Feb;154(2):294-8 [16433799.001]
  • [Cites] Prim Care Respir J. 2005 Apr;14(2):88-98 [16701704.001]
  • [Cites] Clin Exp Allergy. 2007 May;37(5):631-50 [17456211.001]
  • [Cites] J Investig Allergol Clin Immunol. 2009;19(4):299-305 [19639726.001]
  • [Cites] Allergy. 1996 Oct;51(10):666-75 [8904993.001]
  • (PMID = 23055763.001).
  • [ISSN] 1178-7015
  • [Journal-full-title] Clinical, cosmetic and investigational dermatology
  • [ISO-abbreviation] Clin Cosmet Investig Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3459547
  • [Keywords] NOTNLM ; antihistamine / chronic urticaria / dose / histamine / itch / olopatadine
  •  go-up   go-down


10. Macpherson A, Zoheir N, Awang RA, Culshaw S, Ramage G, Lappin DF, Nile CJ: The alpha 7 nicotinic receptor agonist PHA-543613 hydrochloride inhibits Porphyromonas gingivalis-induced expression of interleukin-8 by oral keratinocytes. Inflamm Res; 2014 Jul;63(7):557-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The alpha 7 nicotinic receptor agonist PHA-543613 hydrochloride inhibits Porphyromonas gingivalis-induced expression of interleukin-8 by oral keratinocytes.
  • OKF6/TERT-2 oral keratinocytes were exposed to Porphyromonas gingivalis in the presence and absence of a α7nAChR agonist (PHA-543613 hydrochloride) alone or after pre-exposure to a specific α7nAChR antagonist (α-bungarotoxin).
  • PHA-543613 hydrochloride inhibited P. gingivalis-induced expression of IL-8 at the transcriptional level.
  • PHA-543613 hydrochloride downregulated NF-κB signalling through reduced phosphorylation of the NF-κB p65-subunit.
  • In addition, PHA-543613 hydrochloride promoted STAT-3 signalling by maintenance of phosphorylation.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55633-43 [15489227.001]
  • [Cites] Cell Physiol Biochem. 2011;27(5):605-12 [21691078.001]
  • [Cites] Neuroscience. 2006 Jul 21;140(4):1415-34 [16650942.001]
  • [Cites] Life Sci. 2003 Mar 28;72(18-19):2091-4 [12628462.001]
  • [Cites] Brain Behav Immun. 2007 Aug;21(6):736-45 [17467231.001]
  • [Cites] Inflamm Res. 2012 Sep;61(9):915-26 [22777144.001]
  • [Cites] Mediators Inflamm. 2010;2010:423241 [20379354.001]
  • [Cites] Cell Tissue Res. 2010 May;340(2):347-55 [20309583.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10151-2 [16801534.001]
  • [Cites] Mol Pharmacol. 2003 Oct;64(4):885-9 [14500745.001]
  • [Cites] Nature. 2003 Jan 23;421(6921):384-8 [12508119.001]
  • [Cites] JAKSTAT. 2013 Jan 1;2(1):e23010 [24058791.001]
  • [Cites] J Dent Res. 2000 Apr;79(4):939-49 [10831096.001]
  • [Cites] Periodontol 2000. 2008;48:92-110 [18715360.001]
  • [Cites] Nat Immunol. 2005 Aug;6(8):844-51 [16025117.001]
  • [Cites] Immunology. 1997 Oct;92(2):201-5 [9415027.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1143-8 [11994402.001]
  • [Cites] Arch Oral Biol. 2012 May;57(5):483-90 [22119045.001]
  • [Cites] Int J Mol Sci. 2012;13(2):2219-38 [22408449.001]
  • [Cites] Nat Immunol. 2003 Dec;4(12):1169-76 [14639467.001]
  • [Cites] EMBO Rep. 2009 Apr;10(4):381-6 [19270718.001]
  • [Cites] Nat Protoc. 2008;3(6):1101-8 [18546601.001]
  • [Cites] J Antimicrob Chemother. 1998 Oct;42(4):453-9 [9818743.001]
  • [Cites] Annu Rev Immunol. 1996;14:649-83 [8717528.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):49571-4 [15465828.001]
  • [Cites] Cell Microbiol. 2007 Aug;9(8):1997-2007 [17419719.001]
  • [Cites] Lupus. 2007;16(3):181-5 [17432103.001]
  • [Cites] J Intern Med. 2010 Jul;268(1):94-101 [20337855.001]
  • [Cites] Nucleic Acids Res. 2010 Oct;38(18):6029-44 [20507904.001]
  • [Cites] J Periodontol. 2002 Nov;73(11):1267-72 [12479629.001]
  • [Cites] Indian J Dent Res. 1990 Apr-Sep;2(2-3):166-9 [2096961.001]
  • [Cites] Mol Med. 2009 Jul-Aug;15(7-8):195-202 [19593403.001]
  • [Cites] Nature. 2000 May 25;405(6785):458-62 [10839541.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10193-7 [8234276.001]
  • [Cites] J Invest Dermatol. 1993 Jul;101(1):32-6 [8331294.001]
  • [Cites] J Neurosci. 2008 Jun 4;28(23):5870-8 [18524891.001]
  • [Cites] Infect Immun. 2006 Feb;74(2):1204-14 [16428770.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1783(3):375-82 [18178163.001]
  • [Cites] Infect Immun. 2011 Jul;79(7):2632-7 [21536793.001]
  • [Cites] Am J Physiol Cell Physiol. 2010 Nov;299(5):C903-11 [20660165.001]
  • [Cites] Langenbecks Arch Surg. 2006 Apr;391(2):83-7 [16568325.001]
  • [Cites] Anal Biochem. 2003 Mar 1;314(1):16-29 [12633598.001]
  • [Cites] J Immunol. 2004 May 15;172(10):6336-44 [15128824.001]
  • [Cites] J Immunol. 2010 Jan 1;184(1):401-10 [19949071.001]
  • [Cites] Arthritis Rheum. 2009 May;60(5):1272-81 [19404936.001]
  • [Cites] Life Sci. 2007 May 30;80(24-25):2361-4 [17286990.001]
  • [Cites] Nat Immunol. 2010 Jul;11(7):561-4 [20562838.001]
  • [Cites] Clin Exp Immunol. 2006 Oct;146(1):116-23 [16968406.001]
  • (PMID = 24609617.001).
  • [ISSN] 1420-908X
  • [Journal-full-title] Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  • [ISO-abbreviation] Inflamm. Res.
  • [Language] eng
  • [Grant] United Kingdom / The Dunhill Medical Trust / / R203/0511
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Bridged Bicyclo Compounds, Heterocyclic; 0 / Bungarotoxins; 0 / IL8 protein, human; 0 / Interleukin-8; 0 / Lipopolysaccharides; 0 / N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide; 0 / Quinuclidines; 0 / RNA, Messenger; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Transcription Factor RelA; 0 / alpha7 Nicotinic Acetylcholine Receptor; N9YNS0M02X / Acetylcholine
  • [Other-IDs] NLM/ EMS58142; NLM/ PMC4050294
  •  go-up   go-down






Advertisement